BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma J, Siegel RL, Islami F, Jemal A. Temporal trends in liver cancer mortality by educational attainment in the United States, 2000-2015. Cancer 2019;125:2089-98. [PMID: 30957228 DOI: 10.1002/cncr.32023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Sempokuya T, Warner J, Azawi M, Nogimura A, Wong LL. Current status of disparity in liver disease. World J Hepatol 2022; 14(11): 1940-1952 [DOI: 10.4254/wjh.v14.i11.1940] [Reference Citation Analysis]
2 Islami F, Guerra CE, Minihan A, Yabroff KR, Fedewa SA, Sloan K, Wiedt TL, Thomson B, Siegel RL, Nargis N, Winn RA, Lacasse L, Makaroff L, Daniels EC, Patel AV, Cance WG, Jemal A. American Cancer Society's report on the status of cancer disparities in the United States, 2021. CA Cancer J Clin 2021. [PMID: 34878180 DOI: 10.3322/caac.21703] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
3 Gaysynsky A, Rising CJ, Trivedi N, Blake KD, Chou WS, Oh A, Vanderpool RC. Communication research at the National Cancer Institute, 2013-2019: a grant portfolio analysis. Cancer Causes Control 2021. [PMID: 34313875 DOI: 10.1007/s10552-021-01481-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 2021;134:783-91. [PMID: 33734139 DOI: 10.1097/CM9.0000000000001474] [Cited by in Crossref: 308] [Cited by in F6Publishing: 390] [Article Influence: 308.0] [Reference Citation Analysis]
5 Lei Y, Gan H, Huang Y, Chen Y, Chen L, Shan A, Zhao H, Wu M, Li X, Ma Q, Wang J, Zhang E, Zhang J, Li Y, Xue F, Deng L. Digitoxin inhibits proliferation of multidrug-resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. Oncol Lett 2020;20:71. [PMID: 32863904 DOI: 10.3892/ol.2020.11932] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
6 An BH, Zhang RF, Du XM, Li QL, Cheng S, Huang HL, Ma CL. Novel triorganotin complexes based on phosphonic acid ligands: Syntheses, structures and in vitro cytostatic activity. J Inorg Biochem 2020;206:111022. [PMID: 32070916 DOI: 10.1016/j.jinorgbio.2020.111022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Noonan A, Pawlik TM. Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials. Expert Opinion on Investigational Drugs 2019;28:941-9. [DOI: 10.1080/13543784.2019.1677606] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]